Effect of herbal syrup and solution in treatment of COVID-19

Formulation of two natural products (syrup and solution) and evaluation of their effects in patients with coronavirus disease 2019 (COVID-19): A randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200316046792N1

Enrollment

150

Registered

2020-03-17

Start date

2020-03-16

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: Hospitalized patients will receive 10 cc Corostop solution and 30 cc Coroguard syrup three times daily for 10 days in addition to receiving standard treatments reco

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Laboratory-confirmed COVID-19 cases (2019-nCoV Real-Time RT-PCR ), regardless of the clinical manifestations and history of close contact Both the men and women, aged between 18 to 65 years old Signing informed written consent Highly suspected cases of COVID-19 based on positive findings of chest CT scan

Exclusion criteria

Exclusion criteria: 5 days or more after the onset of illness Pregnancy Breastfeeding History of drug allergy Complicated cases with bacterial infection Patients in recovery phase Critical and severe cases such as ARDS Clinical evidence for respiratory insufficiency at the time of hospitalization (SaO2 =90% or PaO2 < 8 kPa) in the patient breathing room air without oxygen therapy Comorbidities (e.g. renal failure, liver failure, CHF, cerebrovascular and cardiovascular major diseases, chronic pulmonary disease, malignancy, endocrine and metabolic diseases, any immunodeficiency disorders such as AIDS, encephalopathy, neuropathy )

Design outcomes

Primary

Measure	Time frame
Response to the treatment (Significant clinical improvement). Timepoint: At baseline and on the third, fifth, seventh, and tenth days after starting the treatment. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2 ° C), respiratory rate (=24 breaths per minute), oxygen saturation (> 94% at room temperature) and cough (zero or mild) that persist for at least 24 hours. Cough will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.;Complications of the treatment. Timepoint: Daily, until the tenth day. Method of measurement: Interview and patient's record.	—

Measure

Time frame

Response to the treatment (Significant clinical improvement). Timepoint: At baseline and on the third, fifth, seventh, and tenth days after starting the treatment. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2 ° C), respiratory rate (=24 breaths per minute), oxygen saturation (> 94% at room temperature) and cough (zero or mild) that persist for at least 24 hours. Cough will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.;Complications of the treatment. Timepoint: Daily, until the tenth day. Method of measurement: Interview and patient's record.

—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's medical record.;Mortality. Timepoint: End of the treatment. Method of measurement: Patient's medical record (Clinical outcome).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Hossein Jamshidi

Iran University of Medical Sciences

jamshidi.ah@iums.ac.ir+98 21 5563 9666

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026